| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers Z > Headlines for Ziopharm Oncology, Inc. > News item |
Ziopharm receives notice of allowance on use of organic arsenic for treatment of cancer
By Lisa Kerner
Erie, Pa., Jan. 17 - Ziopharm Oncology, Inc. said it received a notice of allowance from the U.S. Patent and Trademark Office for a second organic arsenic use. The allowed claims cover the treatment of cancer using organic arsenics, including ZIO-101, in combination with other agents or therapies, according to a company release.
"We are thrilled to have a very strong patent position for our lead product, ZIO-101, and expect more patent allowances to follow, positioning us with a very firm patent estate for both ZIO-101 and ZIO-201," Ziopharm chief executive officer Jonathan Lewis said in the release.
"Intellectual property protection, rather than just Orphan Drug status alone, is a key element of our strategy for identifying products that are related to successfully marketed cancer agents and developing them for more effective and safer cancer therapy."
ZIO-101 is a novel organic arsenic currently in phase 1 clinical trials in patients with advanced cancers. Data to date suggest ZIO-101 may be active in a broad range of cancers. Given at high doses, ZIO-101 has shown no significant toxicities, the company said.
ZIO-101 is licensed from The University of Texas M. D. Anderson Cancer Center and Texas A&M University .
The company expects to begin a phase 1/2 trial with ZIO-101 as a single agent early this year in patients with advanced myeloma.
Ziopharm has a second organic arsenic drug, ZIO-102, undergoing preclinical study.
New York-based Ziopharm is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of in-licensed cancer drugs
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.